Answers are grounded in this paper and cite their sources.
Evaluation of SGLT2 inhibitors' benefits and local guidelines in T2DM management, indicating the need for enhanced patient education.
Diabetes mellitus, particularly type 2 diabetes mellitus (T2DM), presents a growing public health challenge, with significant implications for cardiovascular and renal health. The introduction of sodium-glucose co-transporter-2 inhibitors (SGLT2i) has transformed management strategies, providing not only glycaemic control but also substantial cardio-renal protective benefits. This article critically evaluates local clinical guidelines from south east London, focusing on the use of SGLT2i in individuals with T2DM and chronic kidney disease. This article reviews pharmacological effects, cardiovascular and renal outcomes, and practical considerations for prescribing and monitoring these agents, including side effects and patient education. The authors also propose the implementation of general practice nurse-led approaches to enhance patient safety and education and promote integrated, patient-centred care.
No takes yet. Share an insight, caveat, or question.
Pignatelli-Ruiz et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: